STRATEGIC-1: multiple-line, randomized, open-label GERCOR-PRODIGE-39 phase III trial in unresectable RAS/BRAF wild-type metastatic colorectal cancer.
- DOI
- 10.1038/s41392-026-02639-y
- Published
- 2026 Apr 14
- Container
- Signal transduction and targeted therapy
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
uncertain Score 53/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- supportingDirectory of Open Access Journals: A matching record was returned by DOAJ.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1038/s41392-026-02639-y,
title = {STRATEGIC-1: multiple-line, randomized, open-label GERCOR-PRODIGE-39 phase III trial in unresectable RAS/BRAF wild-type metastatic colorectal cancer.},
author = {Chibaudel B and Dourthe LM and André T and Henriques J and Bourgeois V and Etienne PL and Desramé J and Carola E and Dupuis O and Baba-Hamed N and Auby D and Louvet C and Maillard E and Romano O and Tournigand C and Garcia-Larnicol ML and Shacham-Shmueli E and Bird BH and Ghiringhelli F and de Gramont A},
year = {2026},
journal = {Signal transduction and targeted therapy},
doi = {10.1038/s41392-026-02639-y},
url = {https://doi.org/10.1038/s41392-026-02639-y}
}RIS
TY - JOUR TI - STRATEGIC-1: multiple-line, randomized, open-label GERCOR-PRODIGE-39 phase III trial in unresectable RAS/BRAF wild-type metastatic colorectal cancer. AU - Chibaudel B AU - Dourthe LM AU - André T AU - Henriques J AU - Bourgeois V AU - Etienne PL AU - Desramé J AU - Carola E AU - Dupuis O AU - Baba-Hamed N AU - Auby D AU - Louvet C AU - Maillard E AU - Romano O AU - Tournigand C AU - Garcia-Larnicol ML AU - Shacham-Shmueli E AU - Bird BH AU - Ghiringhelli F AU - de Gramont A PY - 2026 JO - Signal transduction and targeted therapy DO - 10.1038/s41392-026-02639-y UR - https://doi.org/10.1038/s41392-026-02639-y ER -
APA
B, C., LM, D., T, A., J, H., V, B., PL, E., J, D., E, C., O, D., N, B., D, A., C, L., E, M., O, R., C, T., ML, G., E, S., BH, B., F, G., & A, D. G. (2026). STRATEGIC-1: multiple-line, randomized, open-label GERCOR-PRODIGE-39 phase III trial in unresectable RAS/BRAF wild-type metastatic colorectal cancer.. Signal transduction and targeted therapy. https://doi.org/10.1038/s41392-026-02639-y